Robert Francomano - 22 Jan 2024 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Role
Chief Commercial Officer
Signature
/s/ Robert Francomano
Issuer symbol
SLS
Transactions as of
22 Jan 2024
Net transactions value
$0
Form type
4
Filing time
25 Jan 2024, 06:02:10 UTC
Previous filing
08 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLS Common Stock Award $0 +20,000 +96% $0.000000 40,918 22 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLS Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 22 Jan 2024 Common Stock 30,000 $0.5195 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
F2 One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.